Current PSA level-Between 1 to 4 - Page 2 of 4 Posts on Medivizor
Navigation Menu

Current PSA level-Between 1 to 4 Posts on Medivizor

An analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer

Posted by on Nov 8, 2017 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine which patients  benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination.  Some background A main treatment option for prostate cancer is androgen deprivation...

Read More

The timing of first biopsy and its effect on prostate cancer reclassification

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine the influence of biopsy timing on prostate cancer reclassification during active surveillance.  The authors concluded that the timing of the first biopsy was not related to an increased risk of cancer reclassification, but prostate specific antigen (PSA) and body mass index (BMI – measured based...

Read More

The effect of anxiety and uncertainty on men under prostate cancer active surveillance

Posted by on Mar 4, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine how anxiety and uncertainty affects men with prostate cancer who are undergoing active surveillance.  The authors concluded that uncertainty and urinary complications promote anxiety in men on active surveillance for prostate cancer. They also recommend patient education and management of urinary...

Read More

Can ultrasounds be useful during active surveillance for prostate cancer?

Posted by on Mar 3, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to see if ultrasounds could be used as a tool to monitor low-risk prostate cancer patients in active surveillance. It was concluded that ultrasounds can be used to monitor changes in prostate cancer, and could extend the time between biopsies. Some background Low-risk prostate cancer is cancer that has not...

Read More

Hyopfractioned or standard external beam radiation therapy – which is better?

Posted by on Jul 11, 2016 in Prostate cancer | 0 comments

In a nutshell This study compared external beam radiation therapy (EBRT) and hypofractioned EBRT (H-EBRT) for low-risk localized prostate cancer. Researchers reported no differences in disease progression or survival. However, an increase in side effects was observed with H-EBRT. Some background Radiation therapy is a common treatment for...

Read More

Low-risk prostate cancer management – an overview

Posted by on Jun 6, 2016 in Prostate cancer | 0 comments

In a nutshell This review examined recent findings and recommendations for the management of low-risk localized prostate cancer. Authors concluded that watchful waiting and active surveillance are suitable options for most men with low-risk prostate cancer. Some background Due to advances in the early detection of prostate cancer, many prostate...

Read More

Searching for men with early stage prostate cancer to test a short course of very focused radiation therapy

Posted by on May 9, 2016 in Prostate cancer | 0 comments

In a nutshell This phase 1/2 trial aims to evaluate the effectiveness of a short course of very focused radiation therapy in the treatment of early stage prostate cancer. The main outcome to be investigated is side effects and treatment response. The trial is recruiting in San Diego, California (USA). The details External beam radiation therapy...

Read More

Other medical conditions can affect cancer progression during active surveillance

Posted by on May 6, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the relationship between comorbidities (other medical conditions) and cancer progression during active surveillance. Researchers reported that progression is more likely among men with 2 or more comorbidities.  Some background Active surveillance of prostate cancer refers to actively monitoring tumor growth...

Read More

Looking for prostate cancer patients to evaluate the benefits of hypo-fractionated radiation therapy

Posted by on Aug 7, 2015 in Prostate cancer | 0 comments

In a nutshell This phase III trial aims to determine the effects of hypo-fractionated radiation compared to standard radiation therapy. The main outcome to be investigated is whether hypo-fractionated radiation has similar or better results when compared to standard radiation. This trial is recruiting in in Illinois, Oklahoma and Virginia, in the...

Read More